Community of Best Practices Blog - All Comments

re: Barriers to Advancing Treatment With Insulin Therapy for Type 2 Diabetes Mellitus Patients

ejnpvtawzic — Thu, 08 May 2008 04:06:18 GMT

p1rn4F <a href="rbxhlxwgtkck.com/.../a>, [url=http://tnmjcnzqjlsf.com/]tnmjcnzqjlsf[/url], [link=http://gyigevbmoezg.com/]gyigevbmoezg[/link], http://tyqoqpoxnufo.com/

re: Barriers to Advancing Treatment With Insulin Therapy for Type 2 Diabetes Mellitus Patients

Carlos Campos MD — Thu, 06 Mar 2008 11:29:21 GMT

It appears that tactics to get the A1c below 6.0% were very aggressive; ie. using SU's and prandin combos and etc.

This is one reason ADA recommends only <7%.

re: Barriers to Advancing Treatment With Insulin Therapy for Type 2 Diabetes Mellitus Patients

steve chen — Wed, 13 Feb 2008 13:58:00 GMT

what do you think about the ACCORD trial?

re: Barriers to Advancing Treatment With Insulin Therapy for Type 2 Diabetes Mellitus Patients

Saad Sakkal MD — Wed, 13 Feb 2008 03:30:22 GMT

It is so easy to incorporate the new version of Humalink into any EMR(it is called Rx checker) .it is available on a flash disk with an easy instant upload through any USB slot for desk top ,laptop or any PC.

If you are interested please E mail me

re: Barriers to Advancing Treatment With Insulin Therapy for Type 2 Diabetes Mellitus Patients

Carlos Campos MD — Mon, 11 Feb 2008 23:48:46 GMT

Excellent info, Dr. Sakal. The Humalink software is a option we should consider. I wonder for those of us who have EHR, how this would be incorporated.

Any thoughts, Dr. Nuckols?

re: Barriers to Advancing Treatment With Insulin Therapy for Type 2 Diabetes Mellitus Patients

Saad Sakkal.MD — Wed, 30 Jan 2008 04:08:10 GMT

How to Improve Patients Adherence to DM treatment Guidelines?

Saad Sakal, MD, FACE Anthony Michael Albisser, PhD

Objective: Patients adherence to therapy is a major challenge.Improving adherenc will improve diabetic control .How do we help adherence

Discussion: it is by now well established that the DCCT/EDIC has proven the value good glycemic control for intermed. and long term outcome.But keeping most patient adhering to a therapy is still a major challenge,mostly in the range of 53-65% for oralRx, 60% for diet,19%for exercise,daily BGSM in39% of patients on insulin, and just5% on oral agent/diet/exer. in general TypeI has better adher. a recent article journal in "clin- ical Diabetes" described factors effecting adherence,and as result control,complications and life. Humalink software system has been also proven byond a doubt its effi-cacy,validity,cost effectivness,and safety in a number of studies now in more than 8oo patients.We tested in this study effect on adherence, for near a year.We were very happy to see adherence rate in excellent range(90%) whish is rare in any chronic disease.This adherence led to a better glycemic control aswell as full metabolic control as seen in FBS,PPGluc,HgA1c,Fructosamine, Triglyc.,Cholesterol.And excellent drp in Hypog/Hyerglycemic episodes ,while maintainig stable weight at lower insulin dose. The reason is the collaboration therapy mode whish only Humalink has today.

Conclusions: Humalink offers a 90% adherence rate,with instant feedback,better than any other system or protocol exists today ,at a greater savings,less resources(one MD,RN,clerck),better value index,safety, and cost effectivness.This is a result of its advanced collaboration mode whish makes the patient an active participant in care enjoiying the shared interaction twice weekly whish is within the range most patients will tolerate(40-50%) as most adherence studies shows. Humalink is best well proven system